Study guide

Retinal and optic medication toxicity

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Retinal and optic medication toxicity

Key Takeaways Explain This Topic AI

Current HCQ screening prioritizes OCT and wide-pattern autofluorescence with dose, duration and systemic risk assessment.

Suspected ethambutol neuropathy requires prompt assessment and coordinated TB-treatment revision.

Confirm toxic patterns and distinguish competing disease before changing essential systemic treatment when consultation is possible.

Last updated: October 2026

  • Retinal and Optic Nerve Drug Toxicities
  • 1. Hydroxychloroquine (HCQ) & Chloroquine (CQ) Retinopathy
  • Pathophysiological Mechanism

Hydroxychloroquine and chloroquine possess high structural affinity for melanin and concentrate avidly within the retinal pigment epithelium (RPE) of the macular region. Intracellularly, the drugs inhibit lysosomal enzymatic degradation and interfere with normal autophagy within RPE cells, impairing the digestion of shed photoreceptor outer segments. This leads to secondary metabolic dysfunction and apoptosis of the overlying parafoveal photoreceptor cells (ellipsoid zone loss), followed ultimately by secondary RPE cell death.

Current Hydroxychloroquine Screening

AAO’s 2025 revision, published in 2026, recommends daily HCQ dosing no more than 5 mg/kg actual weight, with additional caution and a 400-mg/day maximum starting approach in severe obesity. This reduces risk rather than defining a guaranteed safe dose. Dose, duration, renal disease, tamoxifen and older age at initiation affect risk.

Obtain baseline fundus examination, OCT and autofluorescence soon after starting. Annual OCT plus wide-pattern FAF are primary screening tools; low-risk patients may defer annual screening during the first five years. Visual fields and mfERG are confirmatory/secondary tests, with field patterns chosen to detect both parafoveal and pericentral disease rather than assigning an exclusive ethnic pattern. The 24-2C can sample both regions. Confirm borderline abnormalities and communicate with the prescriber before stopping an important systemic medicine. Mild toxicity often has limited progression after cessation; severe disease can progress for years.

This is AAO guidance; European/UK local pathways may differ. Use the current jurisdictional protocol and product information. See the AAO revision .

2. Ethambutol Toxic Optic Neuropathy

Ethambutol can cause bilateral central or cecocentral visual loss, dyschromatopsia and later pallor. Risk relates to dose, duration and renal function, without a guaranteed safe threshold. Establish baseline vision and arrange monitoring under the local TB protocol, especially in high-risk patients. New symptoms need urgent examination, central fields and OCT as appropriate, plus communication with the TB team. Withdrawal of the suspected agent should preserve an effective alternative infection regimen. Recovery varies and permanent loss can occur; normal early discs do not exclude toxicity.

3. Other High-Yield Drug Toxicities for the EBOD Exam

Tamoxifen (Selective Estrogen Receptor Modulator):

High cumulative doses induce tamoxifen retinopathy , characterised by numerous refractile, glistening, yellow-white crystalline deposits in the inner retina (paramacular and peripapillary), focal pigmentary changes, and pseudocystic foveal cavitation / cystoid macular oedema.

Phenothiazines (Thioridazine & Chlorpromazine):

Thioridazine: Causes severe, irreversible, dose-dependent pigmentary retinopathy (greater risk at high doses without an absolute safe threshold). Manifests as coarse retinal pigment clumping, "salt and pepper" fundus, geographic nummular chorioretinal atrophy, nyctalopia, and constriction of visual fields.

Chlorpromazine: Produces golden-brown, dust-like granular pigmentary deposits in the corneal endothelium, an anterior subcapsular axial stellate cataract , and violaceous or slate-gray discoloration of the sun-exposed skin and conjunctiva.

Vigabatrin (Sabril - Irreversible GABA-Transaminase Inhibitor):

Used for selected refractory epilepsy and infantile spasms. It can cause irreversible concentric field loss that may be asymptomatic. Assess baseline and follow-up vision according to the current local label and developmental ability. Cooperative patients can undergo perimetry; ERG, OCT or other approaches can be considered when fields are impractical, with their limitations explained. They are not universally equivalent tests. The current UK Sabril SmPC recommends baseline assessment within four weeks, assessment every three to six months during treatment and after discontinuation, using an individualised diagnostic approach.

Phosphodiesterase-5 (PDE5) Inhibitors (Sildenafil, Tadalafil):

Weakly cross-inhibits retinal PDE6 (located in photoreceptor outer segments), causing transient, reversible cyanopsia (blue-tinted vision) , increased light sensitivity, and blurred vision at peak serum concentrations. NAION has been reported in association with PDE5 inhibitors, but shared vascular risks and observational evidence complicate causal attribution. Sudden visual loss requires urgent assessment and coordinated medication review.

Pharmacokinetic and Toxicity Limits

The Henderson–Hasselbalch ratio must specify the drug: for a weak base, ionised/un-ionised ratio is 10 raised to pKa − pH; a weak acid uses the opposite relationship for ionised/un-ionised. Solubility and epithelial integrity affect delivery rather than making every ionised molecule absolutely impenetrable. Nasolacrimal occlusion reduces but does not abolish systemic exposure.

Ethambutol toxicity is associated with dose, duration and renal dysfunction; dyschromatopsia can vary and may not be the first sign. Possible mitochondrial/metal-chelation mechanisms do not prove a single complete pathway. New bilateral central visual dysfunction requires urgent review with the TB team, stopping the suspected agent appropriately while maintaining effective infection treatment. Screening intervals depend on local TB risk/protocol rather than universal monthly testing for all. Vigabatrin monitoring follows the local label and the patient’s ability to perform fields; ERG is not a proven equivalent screening test in every infant. Topical brimonidine is contraindicated below two years, with further caution in older small children; prostaglandin and CAI precautions should not be described as universal contraindications for every uveitis history or sulfonamide-antibiotic allergy.